Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 102

Sort by

Sort Order Select

Journal Articles

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

Maria Lia Palomba, MD, Leo I. Gordon, MD, Tanya Siddiqi, MD, Jeremy S. Abramson, MD, Manali Kamdar, MD, Matthew A. Lunning, DO, FACP, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Jon E. Arnason, MD, Nilanjan Ghosh, MD PhD, Amitkumar Mehta, MD, Scott R. Solomon, MD, Thalia Farazi, MD PhD, Jacob Garcia, MD, Christine Dehner, BSc, Ken Ogasawara, PhD MPH, Jie Gao, PhD, Michael Wang, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136158

Published: 2020

Journal Articles

CD34+ Selected Hematopoietic Cell Boosts (HCB) for Treatment of Refractory Cytopenia Following T-Replete HLA-Haploidentical Transplantation

Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD, Melhem Solh, MD

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-138572

Published: 2020

Journal Articles

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

William G. Wierda, MD PhD, Kathleen A. Dorritie, MD, Javier Munoz, MD, Deborah M. Stephens, DO, Scott R. Solomon, MD, Heidi H. Gillenwater, MD, Lucy Gong, PharmD, Lin Yang, PhD, Ken Ogasawara, PhD MPH, Jerill Thorpe, BS, Tanya Siddiqi, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140622

Published: 2020

Journal Articles

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Blood (2020) 136 (Supplement 1): 21–22.

https://doi.org/10.1182/blood-2020-137221

Published: 2020

Journal Articles

Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching

Ephraim J. Fuchs, MD MBA, Shannon R McCurdy, MD, Scott R. Solomon, MD, Tao Wang, PhD, Michelle Kuxhausen, MS, Yvette L Kasamon, MD, MHD Monzr Al Malki, MD, Shahinaz Gadalla, MD PhD, Sophie Paczesny, MDPhD, Steven GE Marsh, BSc, PhD ARCS, Bronwen E. Shaw, PhD MRCP, FRCPath, Stephen R. Spellman, MS, Stephanie J. Lee, MDMPH, Effie Petersdorf, MD

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-140433

Published: 2020

Journal Articles

SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

Andrea Massimiliano Tomirotti, PhD, Daniela Bellarosa, Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A Strickland, MD MSCI, Roland P Walter, MDPhD, Farhad Ravandi, MBBS, Krzysztof Brzózka, PhD, Milena Mazan, PhD, Simone Baldini, MD, Massimiliano Salerno, Monica Binaschi, PhD, Dirk Laurent, MD, Andrea Pellacani, PhD MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136936

Published: 2020

Journal Articles

Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls

Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Melhem Solh, MD, Scott R. Solomon, MD

Blood (2019) 134 (Supplement_1): 2006.

https://doi.org/10.1182/blood-2019-123230

Published: 2019

Journal Articles

Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation

Asad Bashey, MD PhD, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD, Melhem Solh, MD

Blood (2019) 134 (Supplement_1): 2014.

https://doi.org/10.1182/blood-2019-125229

Published: 2019

Journal Articles

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Scott R. Solomon, MD, Melhem Solh, MD, Stacey Brown, CCRP, Katelin C Jackson, Xu Zhang, PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 1998.

https://doi.org/10.1182/blood-2019-124354

Published: 2019

Journal Articles

Psychological and Social Factors Are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Morbidity Score

Melhem Solh, MD, Dawn Speckhart, PhD, Xu Zhang, PhD, Asad Bashey, MD PhD, Scott R. Solomon, MD, Lawrence E Morris, MD, H. Kent Holland, MD

Blood (2019) 134 (Supplement_1): 3493.

https://doi.org/10.1182/blood-2019-131639

Published: 2019

Journal Articles

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Jeffrey E. Lancet, MD, David A. Rizzieri, MD, Gary J. Schiller, MD, Scott R. Solomon, MD, Laura F. Newell, MD, Harry P. Erba, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1313.

https://doi.org/10.1182/blood-2019-124383

Published: 2019

Journal Articles

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

Tara L. Lin, MD, Daniel H. Ryan, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Jonathan E. Kolitz, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 1316.

https://doi.org/10.1182/blood-2019-124552

Published: 2019

Journal Articles

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, FACP, Michael L. Wang, MD, Jon E. Arnason, MD, Amitkumar Mehta, MD, Enkhtsetseg Purev, MD PhD, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, Scott R. Solomon, MD, Nilanjan Ghosh, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Ana Kostic, Daniel Li, PhD, Yeonhee Kim, Tanya Siddiqi, MD

Blood (2019) 134 (Supplement_1): 241.

https://doi.org/10.1182/blood-2019-127508

Published: 2019

Journal Articles

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Scott R. Solomon, MD, Aziz Nazha, MD, Stephen A. Strickland, MD, Roland B. Walter, MD PhD MS, Ilaria Valimberti, Alessia Tagliavini, Paolo Mazzei, Caterina Fiesoli, Simona Scartoni, Daniela Bellarosa, Monica Binaschi, PhD, Pawel Chrom, MD PhD, Simone Baldini, MD, Krzysztof Brzózka, PhD, Angela Capriati, Andrea Pellacani, PhD MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 3920.

https://doi.org/10.1182/blood-2019-125878

Published: 2019

Journal Articles

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Jonathan E. Kolitz, MD, Daniel H. Ryan, MD, Laura F. Newell, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Gary J. Schiller, MD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3856.

https://doi.org/10.1182/blood-2019-124553

Published: 2019

Journal Articles

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Daniel H. Ryan, MD, Laura F. Newell, MD, Ellen K. Ritchie, MD, Stephen A. Strickland, MD, Donna E. Hogge, MD PhD, Scott R. Solomon, MD, Richard M. Stone, MD, Gary J. Schiller, MD, Matthew J. Wieduwilt, MD PhD, Robert J. Ryan, MS, Stefan Faderl, MD, Jorge E. Cortes, MD

Blood (2019) 134 (Supplement_1): 3842.

https://doi.org/10.1182/blood-2019-124516

Published: 2019

Journal Articles

Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Incidence, Distribution and Response to Therapy

Melhem Solh, MD, Xu Zhang, PhD, Asad Bashey, MD PhD, Lawrence E Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD

Blood (2019) 134 (Supplement_1): 4541.

https://doi.org/10.1182/blood-2019-131661

Published: 2019

Journal Articles

A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide

Melhem Solh, MD, Scott R. Solomon, MD, H. Kent Holland, MD, Lawrence E Morris, MD, Asad Bashey, MD PhD

Blood (2019) 134 (Supplement_1): 4479.

https://doi.org/10.1182/blood-2019-131624

Published: 2019

Journal Articles

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Blood (2019) 134 (Supplement_1): 2651.

https://doi.org/10.1182/blood-2019-127835

Published: 2019

Journal Articles

Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients

Eva Karam, PharmD, Justin LaPorte, PharmD, Connie Sizemore, PharmD, Xu Zhang, PhD, H. Kent Holland, MD, Melhem Solh, MD, Lawrence E Morris, MD, Asad Bashey, MD PhD, Scott R. Solomon, MD

Blood (2019) 134 (Supplement_1): 3269.

https://doi.org/10.1182/blood-2019-131365

Published: 2019

NARROW

Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001

CD34+ Selected Hematopoietic Cell Boosts (HCB) for Treatment of Refractory Cytopenia Following T-Replete HLA-Haploidentical Transplantation

Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens

Improving Donor Selection for Haploidentical Stem Cell Transplantation with Post-Transplant Cyclophosphamide through Selective HLA-Mis/Matching

SEL24/MEN1703 Provides PIM/FLT3 Downstream Pathway Inhibition in Acute Myeloid Leukemia (AML) Blast Cells: Results of the Pharmacodynamics (PD) Assay in the Dose Escalation Part of First-in-Human Diamond Trial

Improved Survival of Patients Diagnosed with Severe (Grade 3-4) Acute GVHD or Severe NIH Grade Chronic GVHD in the Current Era Compared to Historic Controls

Improved Survival in Patients Who Undergo Relapse of Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation

Ixazomib Maintenance to Prevent Alloreactivity and Provide Anti-Malignancy Effects Following Nonmyeloablative T-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Psychological and Social Factors Are a Strong Predictor of Survival after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) Independent of Disease Risk and Morbidity Score

Outcomes in Patients with Therapy-Related Acute Myeloid Leukemia (t-AML) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

First in Human Study of SEL24/MEN1703, First in Class, Orally Available Dual PIM/FLT3 Kinase Inhibitor, in Patients with Acute Myeloid Leukemia

Phase 3 Exploratory Analysis of Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Received Consolidation with CPX-351 Versus Conventional Chemotherapy

Outcomes in Patients with Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Who Achieved Remission with CPX-351 Versus 7+3: Phase 3 Exploratory Analysis

Graft Versus Host Disease (GVHD) after HLA-Mismatched Haploidentical Transplantation with Post-Transplant Cyclophosphamide Compared to Matched Unrelated Donor: Incidence, Distribution and Response to Therapy

A Phase II Trial Evaluating the Efficacy and Safety of Sargramostim Post Infusion of T -Replete HLA Mismatched Peripheral Blood Haploidentical Hematopoietic Stem Cells with Post Transplant Cyclophosphamide

SEL120 - a First-in-Class CDK8/19 Inhibitor As a Novel Option for the Treatment of Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome - Data from Preclinical Studies and Introduction to a Phase Ib Clinical Trial

Real World Outcomes of Letermovir Prophylaxis in Unselected High Risk CMV Seropositive Hematopoietic Stem Cell Transplant Recipients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only